MAPT and Alzheimer disease: Contributions of the C5a/C5aR axis were tested using the C5aR antagonist PMX205 in the 3xTG AD model (includes the P301L tau mutation); treatment for 3 months reduced tau hyperphosphorylation and rescued cognitive function compared with controls [117].